As part of a feasibility study, Royal Adelaide Hospital in South Australia has performed the first procedure using St. Jude Medical’s renal denervation catheter and generator system to treat resistant hypertension.
The design of the new catheter minimises the need for extensive catheter manipulation, which could potentially shorten procedure times, limit contrast use and reduce fluoroscopic exposure.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
St. Jude Medical Cardiovascular Division president Frank Callaghan said the new technology could potentially benefit patients through an overall reduction in risks for cardiovascular side effects of hypertension, including death.
“We have leveraged our company’s extensive experience in ablation technologies to develop a renal denervation system that provides physicians with an alternative therapeutic option for patients with resistant hypertension,” Callaghan said.
The company expects a limited market launch in Europe before the end of 2012.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
